← Browse by Condition
Medical Condition
esophageal squamous cell carcinoma
Total Trials
15
Recruiting Now
15
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for esophageal squamous cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — esophageal squamous cell carcinoma Clinical Trials
How many clinical trials are currently recruiting for esophageal squamous cell carcinoma?
ClinicalMetric currently tracks 15 actively recruiting clinical trials for esophageal squamous cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for esophageal squamous cell carcinoma?
esophageal squamous cell carcinoma research spans Phase 1 (3 trials), Phase 2 (9 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a esophageal squamous cell carcinoma clinical trial?
Eligibility criteria for esophageal squamous cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 9
Phase 3 1
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07452601 Phase 2
Recruiting
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Enrollment
90 pts
Location
China
Sponsor
Tang-Du Hospital
NCT06561178
Recruiting
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
Enrollment
50 pts
Location
China
Sponsor
Sun Yat-Sen University Cancer ...
NCT07088354
Recruiting
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
Enrollment
300 pts
Location
China
Sponsor
Tongji Hospital
NCT06047379 Phase 1, Phase 2
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Enrollment
134 pts
Location
United States
Sponsor
Neonc Technologies, Inc.
NCT04290806
Recruiting
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Enrollment
1,900 pts
Location
Germany
Sponsor
iOMEDICO AG
NCT04807673 Phase 3
Recruiting
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Enrollment
342 pts
Location
China
Sponsor
Tianjin Medical University Can...
NCT04510129
Recruiting
A Multicenter Cancer Biospecimen Collection Study
Enrollment
1,650 pts
Location
United States
Sponsor
Cofactor Genomics, Inc.
NCT07188103 Phase 2
Recruiting
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Enrollment
37 pts
Location
China
Sponsor
Anhui Provincial Hospital
NCT07403136 Phase 2
Recruiting
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Enrollment
104 pts
Location
China
Sponsor
Fudan University
NCT07266493 Phase 2
Recruiting
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Enrollment
26 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
NCT07217171 Phase 1
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Enrollment
160 pts
Location
United States
Sponsor
EvolveImmune United, Inc
NCT06186609 Phase 2
Recruiting
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Enrollment
68 pts
Location
China
Sponsor
Affiliated Hospital of Nantong...
NCT06988956 Phase 2
Recruiting
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Enrollment
95 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT05978193 Phase 2
Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Enrollment
100 pts
Location
China
Sponsor
Shanghai Chest Hospital
NCT07385001 Phase 1, Phase 2
Recruiting
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Enrollment
45 pts
Location
China
Sponsor
Tang-Du Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology